XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05005728
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
72 participants
INTERVENTIONAL
2021-10-22
2025-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
NCT05733351
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
NCT05551117
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
NCT02111577
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
NCT02522715
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
NCT03204812
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase 2, open-label, multiple-dose, multiple-arm, parallel assignment study in patients with mCRPC who have progressed on prior therapy. It will enroll subjects into 1 of 5 molecularly defined cohorts based on the results of acceptable, documented prior diagnostic testing:
* Cohort A: Aggressive variant prostate cancer (AVPCa)
* Cohort B: Homologous recombination deficient (HRD)/cyclin-dependent kinase 12 (CDK12) biallelic loss tumors that have progressed on poly-adenosine diphosphate ribose polymerase inhibitors (HRD/CDK12 PARP Progressors) - Closed to Enrollment
* Cohort C: HRD/CDK12 biallelic loss tumors, naive to PARP inhibitors (HRD/CDK12 PARP Naïve) - Closed to Enrollment
* Cohort D: Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD), or tumor mutational burden-high (TMB-H) tumors - Closed to Enrollment
* Cohort E: No Targetable Mutations
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A - AVPCa
vudalimab + carboplatin + cabazitaxel
Vudalimab IV, carboplatin IV, cabazitaxel IV
Cohort B - HRD/CDK12 PARP - Progressors
vudalimab + cabazitaxel or docetaxel
Vudalimab IV, cabazitaxel or docetaxel IV
Cohort C - HRD/CDK12 PARP Naïve
vudalimab + olaparib
Vudalimab IV, olaparib oral
Cohort D - MSI-H, MMRD or TMB-H
vudalimab monotherapy
Vudalimab IV
Cohort E - No Targetable Mutations
vudalimab + docetaxel
Vudalimab IV, docetaxel IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vudalimab + carboplatin + cabazitaxel
Vudalimab IV, carboplatin IV, cabazitaxel IV
vudalimab + olaparib
Vudalimab IV, olaparib oral
vudalimab monotherapy
Vudalimab IV
vudalimab + docetaxel
Vudalimab IV, docetaxel IV
vudalimab + cabazitaxel or docetaxel
Vudalimab IV, cabazitaxel or docetaxel IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult (age ≥ 18 years)
* Histologically confirmed diagnosis of carcinoma of the prostate
* Documented progressive mCRPC based on at least one of the following criteria:
* PSA progression, defined as at least 2 rises in PSA with a minimum of a 1-week interval
* Soft-tissue progression per RECIST 1.1
* Progression of bone disease (evaluable disease) or 2 or more new bone lesions by bone scan
* Prostate cancer must have progressed following treatment including at least 1 androgen receptor signaling inhibitor (ARSI) agent
* Subjects who did not have a surgical orchiectomy must be on androgen suppression treatment (eg, luteinizing hormone-releasing hormone agonist) with castrate level of testosterone (≤ 50 ng/dL) and be willing to continue the treatment throughout the study
* Prior targeted or whole exome sequencing panel performed by CLIA-certified laboratory documenting:
1. Cohort A (AVPCa) - Aggressive variant prostate cancer
2. Cohort B or C (HRD) - Homologous recombination deficient (HRD) tumor
3. Cohort D (MSI-H/MMRD) - Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD) tumors (MSI-H/MMRD) or TMB-H (≥ 10 mut/Mb)
4. Cohort E (No Targetable Mutations)
NOTE: Cohorts B, C, and D are no longer open for enrollment
* Evaluable disease according to PCWG3 criteria
* Adequate archival metastatic tumor tissue or agree to undergo a biopsy of at least 1 metastatic site (fresh biopsy of primary prostate is only allowed if there is clear local disease and no other measurable disease site or biopsiable bone lesion)
* ECOG performance status of 0 or 1
* Able and willing to complete the study according to the study schedule
Exclusion Criteria
* Prior treatment with docetaxel (Cohort E only)
* Treatment with any other anticancer therapy within 2 weeks of the start of study drug (ie, other immunotherapy, chemotherapy, radiation therapy, etc.)
* Disease progression on prior treatment with cabazitaxel plus carboplatin (applicable to subjects eligible for Cohort A) or cabazitaxel alone (applicable to subjects eligible for Cohort E)
* Prior treatment with any cytotoxic T-lymphocyte-associated protein (CTLA4), PD1, PDL1, or programmed cell death ligand 2 (PDL2) directed immunotherapy, except subjects in Cohort D, who will have had prior FDA-approved checkpoint inhibitor therapy
* Failure to recover from any toxicity related to previous anticancer treatment to ≤ Grade 2
* Have known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), are clinically stable, and are without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
* Platelet count \< 100 × 109/L
* Hemoglobin level ≤ 9.0 g/dL
* Absolute neutrophil count ≤ 1.7 × 109 for subjects who will receive cabazitaxel; \< 1.0 × 109/L for all others
* Aspartate aminotransferase at screening \> 3 × upper limit of normal (ULN) for subjects without known liver involvement by tumor or \> 5 × ULN for subjects with known liver involvement by tumor
* Alanine aminotransferase at screening \> 3 × ULN for subjects without known liver involvement by tumor or \> 5 × ULN for subjects with known liver involvement by tumor
* Bilirubin ≥ 1.5 × ULN (unless prior diagnosis and documentation of ongoing hemolysis or Gilbert's syndrome has been made)
* Estimated creatinine clearance \< 50 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas
* Active known or suspected autoimmune disease (except vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs)
* Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response). Subjects who are currently taking prednisone from a previous prostate cancer therapy will be permitted to enroll in the study.
* Receipt of an organ allograft
* Known history of left ventricular ejection fraction ≤ 40%
* History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease other than their primary malignancy that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study evaluations, procedures, or completion
* Evidence of any serious bacterial, viral, parasitic, or systemic fungal infections within the 30 days prior to the first dose of study drug
* Receipt of a live-virus vaccine within 30 days prior to the first dose of study drug (seasonal flu vaccines that do not contain live virus are permitted)
* Positive test for hepatitis C RNA (a subject who is hepatitis C virus \[HCV\] antibody positive but HCV RNA negative due to documented, curative prior antiviral treatment or natural resolution is eligible)
* Positive test for HBsAg or HBcAb (a subject whose HBsAg is negative and HBcAb is positive may be enrolled if a HBV DNA test is negative and the subject is retested for HBsAg and HBV DNA every 2 months)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xencor, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jolene Shorr
Role: STUDY_DIRECTOR
Xencor, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alaska Oncology and Hematology
Anchorage, Alaska, United States
Palo Verde Hematology Oncology
Glendale, Arizona, United States
Mayo Clinic Hospital
Phoenix, Arizona, United States
City of Hope
Duarte, California, United States
VA Greater Los Angeles
Los Angeles, California, United States
University of California, San Diego
San Diego, California, United States
Rocky Mountain Cancer Centers
Lone Tree, Colorado, United States
Mayo Clinic
Jacksonville, Florida, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
University of Kansas Clinical Research Center
Fairway, Kansas, United States
Mayo Clinic
Rochester, Minnesota, United States
GU Research Network/Urology Cancer Center
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
XCancer New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico, United States
Columbia University
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Northwest Cancer Specialists
Tigard, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Texas Oncology-Central South
Weslaco, Texas, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
University of Washington/Seattle Cancer Care/Alliance
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XmAb20717-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.